Anesiva Defines Regulatory Pathway For Adlea With FDA
Oct 11th 2007Drug InformationPain / Anesthetics
Anesiva, Inc. (Nasdaq: ANSV) announced that it will conduct two Phase 3 clinical trials for the approval of Adlea(TM) — one of which has already been planned in total knee replacement surgeries — and the second trial in bunionectomy surgeries — for a broad product label of management of post-surgical pain associated with orthopedic surgeries. This decision is the result of continuing conversations with the Food and Drug Administration (FDA). [click link for full article]
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
